399 related articles for article (PubMed ID: 17679808)
1. Dyslipidemia in the metabolic syndrome in children.
Gidding SS
J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
[TBL] [Abstract][Full Text] [Related]
2. Association of age and sex with cardiovascular risk factors and insulin sensitivity in overweight children and adolescents.
Koenigsberg J; Boyd GS; Gidding SS; Hassink SG; Falkner B
J Cardiometab Syndr; 2006; 1(4):253-8. PubMed ID: 17679813
[TBL] [Abstract][Full Text] [Related]
3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
[TBL] [Abstract][Full Text] [Related]
5. Atherogenic dyslipidemia.
Hayden MR
J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
[No Abstract] [Full Text] [Related]
6. Effect of body mass index on insulin resistance and lipids in prepubertal and postpubertal children: SCHOOL observations.
Murdock DK; Olson KJ; Juza RM; Hendricks BL
J Cardiometab Syndr; 2006; 1(4):242-7. PubMed ID: 17679804
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome: controversial but useful.
Stolar M
Cleve Clin J Med; 2007 Mar; 74(3):199-202, 205-8. PubMed ID: 17375800
[TBL] [Abstract][Full Text] [Related]
8. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II).
Deedwania PC; Maki KC; Dicklin MR; Stone NJ; Ballantyne CM; Davidson MH
J Cardiometab Syndr; 2006; 1(5):295-300. PubMed ID: 17679790
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic dyslipidemia in the cardiometabolic syndrome.
Govindarajan G; Chowdhury N; Flaker G
J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
[No Abstract] [Full Text] [Related]
10. Management of dyslipidemia in the metabolic syndrome.
Tan KC
Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):99-108. PubMed ID: 17584044
[TBL] [Abstract][Full Text] [Related]
11. Severe dyslipidemia and concomitant risk factors in the middle-aged Lithuanian adults: a cross-sectional cohort study.
Kutkienė S; Petrulionienė Ž; Laucevičius A; Petrylaitė M; Maskeliūnaitė D; Puronaitė R; Kovaitė M; Kalibaitaitė I; Rinkūnienė E; Dženkevičiūtė V; Kasiulevičius V
Lipids Health Dis; 2018 Apr; 17(1):88. PubMed ID: 29673349
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome.
Opie LH
Circulation; 2007 Jan; 115(3):e32-5. PubMed ID: 17242286
[No Abstract] [Full Text] [Related]
13. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
14. Obesity and lipids.
Miller WM; Nori-Janosz KE; Lillystone M; Yanez J; McCullough PA
Curr Cardiol Rep; 2005 Nov; 7(6):465-70. PubMed ID: 16256017
[TBL] [Abstract][Full Text] [Related]
15. The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor.
Espinosa-Larrañaga F; Vejar-Jalaf M; Medina-Santillán R;
Diab Vasc Dis Res; 2005 Oct; 2 Suppl 1():S1-8. PubMed ID: 16342610
[TBL] [Abstract][Full Text] [Related]
16. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Graham I; Atar D; Borch-Johnsen K; Boysen G; Burell G; Cifkova R; Dallongeville J; De Backer G; Ebrahim S; Gjelsvik B; Herrmann-Lingen C; Hoes A; Humphries S; Knapton M; Perk J; Priori SG; Pyorala K; Reiner Z; Ruilope L; Sans-Menendez S; Op Reimer WS; Weissberg P; Wood D; Yarnell J; Zamorano JL; Walma E; Fitzgerald T; Cooney MT; Dudina A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Funck-Brentano C; Filippatos G; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Altiner A; Bonora E; Durrington PN; Fagard R; Giampaoli S; Hemingway H; Hakansson J; Kjeldsen SE; Larsen mL; Mancia G; Manolis AJ; Orth-Gomer K; Pedersen T; Rayner M; Ryden L; Sammut M; Schneiderman N; Stalenhoef AF; Tokgözoglu L; Wiklund O; Zampelas A; ; ; ; ; ; ; ; ; ; ;
Eur J Cardiovasc Prev Rehabil; 2007 Sep; 14 Suppl 2():S1-113. PubMed ID: 17726407
[No Abstract] [Full Text] [Related]
17. Preventing cardiovascular disease and diabetes: a call to action from the ADA and AHA.
Wyne KL
J Cardiometab Syndr; 2006; 1(3):220-1. PubMed ID: 17679801
[No Abstract] [Full Text] [Related]
18. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
Raal FJ
Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome.
Soares EM; Azevedo GD; Gadelha RG; Lemos TM; Maranhão TM
Fertil Steril; 2008 Mar; 89(3):649-55. PubMed ID: 17543961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
